Colecalciferol EQL Pharma Approval

The pharmaceutical Colecalciferol EQL Pharma tablets 800IU and 2000IU has been approved by the Irish Medicines Agency (HPRA) for sale. Approvals are also expected soon from the Netherlands, Norway and Sweden.

Colecalciferol EQL Pharma is a prescription drug that contains Vitamin D3, which helps with the uptake and storage of calcium in the skeleton. It is often given as a preventive treatment for osteoporosis.

Colecalciferol EQL Pharma will be launched in Sweden during the company's fourth financial quarter. In Sweden, the market today is valued at SEK 69m with two active competitors. For the other countries, no launch date has yet been set.

For further information, please contact:
Christer Fåhraeus
CEO, EQL Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com

EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e. medicines that are medically equivalent to originator medicines. The company currently has 17 niche generics (i.e. generics with little or no competition apart from the originator drug) approved in the Nordic markets. In addition to these, there exist a significant pipeline of additional niche generics for launch in 2021 and beyond. The business is currently entirely focused on prescription drugs. EQL Pharma AB conducts its operations in Lund, employs 10 people and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU, India and China, among others.